Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27576906.
- Also identified by DOI 10.1093/jnci/djw183 and PMC identifier 6284257.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of cancer mutations with potential applicability to personalized medicine and future therapeutic use.
Medical subject headings
- Bacterial Proteins
- Carcinoma
- Clustered Regularly Interspaced Short Palindromic Repeats
- Colonic Neoplasms
- Endonucleases
- Leukemia, Myeloid, Acute
- Mutation
- RNA, Guide, CRISPR-Cas Systems